The present study was carried out to evaluate the effect of a new derivative VMA-10-18 (10 mg/kg) on the resistance of mice to acute hypobaric hypoxia. It was confirmed that the studied derivative contributes to an increase in the life time on the lethal test site by 2,7 times (p <0,05) compared with the control group of animals and exceeds the strength of the effect of the reference drug Metaprot by 1,2 (p <0,05).

This study was aimed to assess the effect of a new pyrimidine derivative (PIR-12 50 mg/kg) on survival and neurological deficits in rat global brain ischemia. It has been confirmed that the investigated compound PIR-12 contributes to an increase in survival up to 80% and a decrease in neurological status by 73,3% compared to the control group of animals and exceeds the strength of the effect of the reference drug Cavinton by 30% and 22,48%, respectively.